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Abstract
IMPORTANCE Millions of Americans gained insurance through the state expansion of Medicaid, but
several states with large populations of racial/ethnic minorities did not expand their programs.
OBJECTIVE To investigate the implications of Medicaid expansion for liver transplant (LT) wait-
listing trends for racial/ethnic minorities.
DESIGN, SETTING, AND PARTICIPANTS A cohort study was performed of adults wait-listed for LT
using the United Network of Organ Sharing database between January 1, 2010, and December 31,
2017. Poisson regression and a controlled, interrupted time series analysis were used to model trends
in wait-listing rates by race/ethnicity. The setting was LT centers in the United States.
MAIN OUTCOMES AND MEASURES (1) Wait-listing rates by race/ethnicity in states that expanded
Medicaid (expansion states) compared with those that did not (nonexpansion states) and (2) actual
vs predicted rates of LT wait-listing by race/ethnicity after Medicaid expansion.
RESULTS There were 75 748 patients (median age, 57.0 [interquartile range, 50.0-62.0] years;
48 566 [64.1%] male) wait-listed for LT during the study period. The cohort was 8.9% Black and
16.4% Hispanic. Black patients and Hispanic patients were statistically significantly more likely to be
wait-listed in expansion states than in nonexpansion states (incidence rate ratio [IRR], 1.54 [95% CI,
1.44-1.64] for Black patients and 1.21 [95% CI, 1.15-1.28] for Hispanic patients). After Medicaid
expansion, there was a decrease in the wait-listing rate of Black patients in expansion states (annual
percentage change [APC], −4.4%; 95% CI, −8.2% to −0.6%) but not in nonexpansion states (APC,
0.5%; 95% CI, −4.0% to 5.2%). This decrease was not seen when Black patients with hepatitis C virus
(HCV) were excluded from the analysis (APC, 3.1%; 95% CI, −2.4% to 8.9%), suggesting that they
may be responsible for this expansion state trend. Hispanic Medicaid patients without HCV were
statistically significantly more likely to be wait-listed in the post–Medicaid expansion era than would
have been predicted without Medicaid expansion (APC, 13.2%; 95% CI, 4.0%-23.2%).
CONCLUSIONS AND RELEVANCE This cohort study found that LT wait-listing rates have decreased
for Black patients with HCV in states that expanded Medicaid. Conversely, wait-listing rates have
increased for Hispanic patients without HCV. Black patients and Hispanic patients may have
benefited differently from Medicaid expansion.
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Key Points
Question Was state Medicaid
expansion associated with increased
liver transplant wait-listing rates for
racial/ethnic minorities?
Findings In this cohort study of 75 748
patients, wait-listing rates were higher
in Black patients and Hispanic patients
living in expansion states compared with
those living in nonexpansion states, and
there was a statistically significant
decrease in the wait-listing rate of Black
patients in expansion states after
Medicaid expansion that was not seen
when Black patients with hepatitis C
virus were excluded from the analysis.
Hispanic patients without hepatitis C
virus were wait-listed at higher rates
than would have been predicted
without Medicaid expansion.
Meaning Black patients and Hispanic
patients may have benefited differently
from Medicaid expansion.
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Introduction
Liver transplant (LT) is the standard-of-care and life-saving treatment for end-stage liver disease
(ESLD). Although comprehensive national data do not exist on the exact burden of ESLD, data
suggest racial/ethnic disparities in access to LT wait-listing.1,2 This finding is not entirely unexpected
because disparities earlier in the care continuum have been described in access to hepatitis C virus
(HCV) therapy, treatment for cirrhosis complications, and referral for LT.3-5 Once racial/ethnic
minority patients are wait-listed for LT, Model for End-Stage Liver Disease era data suggest that
transplant rates are similar to those of White candidates.6 Therefore, a critical step in achieving
equitable care of patients with ESLD is ensuring access to LT wait-listing.
Financial screening is the first step in the LT evaluation process.7 This step poses a substantial
barrier to many patients. More than one-quarter of transplant ethics consultations describe
restrictions in transplant-related treatment for financial or insurance reasons.8
In 2013, approximately 44 million Americans were uninsured (40.5% of Hispanic individuals,
25.8% of Black individuals, and 14.8% of White individuals).9,10 In 2014, the Affordable Care Act
(ACA) sought to expand insurance coverage through an optional state-level expansion of
Medicaid.11,12 After the main ACA provisions went into effect in 2014, the percentage of adults who
were uninsured decreased by 7.1% for Hispanic patients, 5.1% for Black patients, and 3% for White
patients.9 Coverage gains were greater in states that expanded Medicaid programs.9 Several states
that did not expand their Medicaid programs have large populations of racial/ethnic minorities.13
Analysis to date on the association of Medicaid expansion with LT wait-listing has included only
1 year of data before and after expansion, provided limited or no analysis of race/ethnicity, focused
broadly on all solid organ transplantation, or used difference-in-differences methods that did not
account for trends that were already under way before Medicaid expansion.14-16 We hypothesized
that insurance status would be a barrier to LT wait-listing for racial/ethnic minorities and that
Medicaid expansion would be associated with higher wait-listing rates for racial/ethnic minorities
living in states that expanded Medicaid.
Methods
Study Population and Design
A cohort study was performed of adult patients wait-listed for LT at LT centers in the United States
between January 1, 2010, and December 31, 2017. Main outcomes and measures were (1) wait-listing
rates by race/ethnicity in states that expanded Medicaid (expansion states) compared with those
that did not (nonexpansion states) and (2) actual vs predicted rates of LT wait-listing by race/
ethnicity after Medicaid expansion. The United Network for Organ Sharing (UNOS) maintains a
database of all organ transplant data in the United States. These data include all candidates wait-
listed for LT. This study was reviewed by an Indiana University School of Medicine institutional review
board. It was deemed exempt from patient informed consent because deidentified data were used
for the analysis. This study followed the Strengthening the Reporting of Observational Studies in
Epidemiology (STROBE) reporting guideline.
The first round of Medicaid expansion occurred on January 1, 2014. Therefore, the post–
Medicaid expansion era was defined as the period between January 1, 2014, and December 31, 2017.
The pre–Medicaid expansion era was defined as the period between January 1, 2010, and December
31, 2013.
States that expanded Medicaid during the first round of expansion were called expansion states
(Figure 1). States that never expanded were called nonexpansion states (Figure 1). States that
expanded after January 1, 2014 (Idaho, Indiana, Louisiana, Maine, Montana, Nebraska, New
Hampshire, Pennsylvania, Utah, and Virginia), were excluded from this analysis to allow for
meaningful follow-up and the ability to assess trends with less confounding (Figure 1).
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To account for changes in state population over time, a State Health Access Data Assistance Center
population data set was obtained on July 8, 2019. The data were stratified by state, age, and race/
ethnicity for 2010 to 2017. The University of Minnesota analyzes national population data from the
American Community Survey and makes the data sets publicly available.17 After excluding states that
expanded Medicaid after January 1, 2014, and residents younger than 18 years, the total adult population
for expansion states and nonexpansion states was calculated for each year, stratified by race/ethnicity.
This population was combined with data from the UNOS database to create a data set containing the
number of individuals wait-listed with each insurance type within each year and each race/ethnicity.
Covariates
Race/ethnicity was categorized as White, Black, Hispanic, or Asian based on UNOS classification.
Patients of American Indian, Alaskan native, or Hawaiian/Pacific Islander descent and multiracial
patients were categorized as other race/ethnicity.
The causes of liver disease were defined using UNOS primary diagnosis codes for acute liver
failure from any cause, alcoholic liver disease (ALD) (alcoholic cirrhosis or acute alcoholic hepatitis),
autoimmune liver disease, cholestatic liver diseases (primary biliary cholangitis, primary sclerosing
cholangitis, or biliary cirrhosis), graft failure, hepatitis B virus (hepatitis B, hepatitis B, and hepatitis
D), HCV (hepatitis C, hepatitis C and hepatitis B, or hepatitis C and alcoholic), nonalcoholic
steatohepatitis (NASH), and other. Patients with a primary diagnosis code of NASH or cryptogenic
cirrhosis who had a body mass index (calculated as weight in kilograms divided by height in meters




























































In 2014, the Affordable Care Act sought to expand insurance coverage through an optional state-level expansion of Medicaid. The map identifies states with higher populations of
racial/ethnic minorities.
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squared) exceeding 30 were defined as having NASH. Insurance type was obtained from the UNOS
database and defined as private, Medicaid, Medicare, or other.
Statistical Analysis
Demographic and clinical variables for patients wait-listed in expansion states and nonexpansion
states in the pre–Medicaid expansion and post–Medicaid expansion eras were described with
summary statistics. The wait-listing rate for patients with ALD, HCV, or NASH was calculated for
expansion states and nonexpansion states within each racial/ethnic group from 2010 to 2017.
The average incidence rate ratios (IRRs) comparing wait-listing rates in expansion states vs
nonexpansion states were calculated before and after Medicaid expansion. The average IRR was
calculated for the overall population and by race/ethnicity.
There are multiple factors that impact trends in LT wait-listing, and it is possible that trends
were already occurring before Medicaid expansion. Therefore, to conjecture that a trend is
associated with Medicaid expansion, the post–Medicaid expansion trajectory should be different
than what would be predicted by the pre–Medicaid expansion trajectory. As such, segmented
Poisson regression was used to conduct a controlled, interrupted time series analysis to compare
actual vs predicted trend changes for LT wait-listing rates in expansion states compared with
nonexpansion states. The Poisson regression was used to model trends in LT wait-listing rates in
expansion states and nonexpansion states before and after Medicaid expansion for patients with
private insurance, Medicaid, Medicare, or other insurance and overall for the full cohort, as well as by
race/ethnicity. Both level and slope changes were allowed to account for immediate and gradual
consequences of Medicaid expansion. From this model, annual percentage change (APC) in wait-
listing rates adjusted for state population changes was estimated for expansion states and
nonexpansion states. The IRRs comparing the observed wait-listing rate with what would have been
observed if pre–Medicaid expansion trends had continued were also estimated for each year. The
trend in those IRRs was further summarized by calculating the average APC.
Because Medicaid expansion occurred in 2014 at the same time as the market release of direct-
acting antiviral agents (DAAs) for HCV, the previously mentioned analyses were also performed by
excluding patients with HCV. The analyses were also performed excluding patients with
hepatocellular carcinoma (HCC).
All analytic assumptions were tested and verified. Analyses were conducted in R, version 3.6.0
(R Core Team). Figures were produced using the ggplot2 package by Wickham.18 All tests were 2
sided, and P < .05 was considered statistically significant for all statistical tests.
Results
Among 75 748 patients wait-listed for LT during the study period, the median age was 57.0 years
(interquartile range [IQR], 50.0-62.0 years); 48 566 (64.1%) were male, and 27 182 (35.9%) were
female. The proportion of Black individuals and Hispanic individuals in the cohort was 8.9% and
16.4%, respectively. The Black population and Hispanic population were greater than 25% in the
following nonexpansion states: Alabama, Georgia, Mississippi, South Carolina, and Texas (Figure 1).
Differences Between Patients Wait-listed Before vs After Medicaid Expansion
Patients were slightly younger in the pre–Medicaid expansion era compared with the post–Medicaid
expansion era in expansion states (57.0 [IQR, 50.0-62.0] years vs 58.0 [IQR, 51.0-63.0] years) and
nonexpansion states (median, 56.0 [IQR, 50.0-61.0] years vs 58.0 [IQR, 50.0-63.0] years) (Table).
The number of Hispanic patients wait-listed for LT increased in the post–Medicaid expansion era in
both expansion states and nonexpansion states (from 17.9% to 18.2% in expansion states and from
12.8% to 14.5% in nonexpansion states) (Table).
The proportion of patients wait-listed with ALD or NASH was higher in the post–Medicaid
expansion era in expansion states and nonexpansion states (Table and eFigure 1 in the Supplement). The
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proportion of patients wait-listed with HCV was lower in the post–Medicaid expansion era in expansion
states and nonexpansion states (Table and eFigure 1 in the Supplement). The proportion of patients with
HCC increased in the post–Medicaid expansion era in expansion states and nonexpansion states.
The proportion of patients wait-listed and working for income in the post–Medicaid expansion
era was similar in expansion states (22.1%) and nonexpansion states (21.8%). Educational attainment
was also similar in the post–Medicaid expansion era for patients in expansion states and
nonexpansion states (41.4% with high school completion after Medicaid expansion in expansion
states and 41.2% with high school completion in nonexpansion states) (Table).
Table. Demographic and Clinical Characteristics of Patients Wait-listed for Liver Transplant in Expansion States and Nonexpansion States
in the Pre–Medicaid Expansion Era and Post–Medicaid Expansion Era
Variable
No./total No. (%)
Expansion states Nonexpansion states
Total
(N = 75 748)
Before Medicaid expansion
(n = 23 017)
After Medicaid expansion
(n = 23 858)
Before Medicaid expansion
(n = 14 001)
After Medicaid expansion
(n = 14 872)
Age, median (IQR), y 57.0 (50.0-62.0) 58.0 (51.0-63.0) 56.0 (50.0-61.0) 58.0 (50.0-63.0) 57.0 (50.0-62.0)
Sex
Male 15 078 (65.5) 15 247 (63.9) 8821 (63.0) 9420 (63.3) 48 566 (64.1)
Female 7939 (34.5) 8611 (36.1) 5180 (37.0) 5452 (36.7) 27 182 (35.9)
Race/ethnicity
White 15 171 (65.9) 15 682 (65.7) 10 324 (73.7) 10 653 (71.6) 51 830 (68.4)
Black 1899 (8.3) 1940 (8.1) 1388 (9.9) 1488 (10.0) 6715 (8.9)
Hispanic 4128 (17.9) 4353 (18.2) 1792 (12.8) 2156 (14.5) 12 429 (16.4)
Asian 1495 (6.5) 1484 (6.2) 279 (2.0) 341 (2.3) 3599 (4.8)
Other 324 (1.4) 399 (1.7) 218 (1.6) 234 (1.6) 1175 (1.6)
Diagnosis
Acute liver failure from any
cause
1812 (7.9) 1400 (5.9) 982 (7.0) 759 (5.1) 4953 (6.5)
Alcoholic liver disease 3830 (16.6) 5615 (23.5) 2244 (16.0) 3340 (22.5) 15 029 (19.8)
Autoimmune liver disease 611 (2.7) 655 (2.7) 414 (3.0) 488 (3.3) 2168 (2.9)
Cholestatic liver diseases 1724 (7.5) 1809 (7.6) 1027 (7.3) 1027 (6.9) 5587 (7.4)
Graft failure 140 (0.6) 392 (1.6) 93 (0.7) 320 (2.2) 945 (1.2)
HBV 727 (3.2) 684 (2.9) 223 (1.6) 220 (1.5) 1854 (2.4)
HCV 9164 (39.8) 6987 (29.3) 5135 (36.7) 3856 (25.9) 25 142 (33.2)
NASH 2558 (11.1) 3926 (16.5) 1954 (14.0) 3004 (20.2) 11 442 (15.1)
Other 2451 (10.6) 2390 (10.0) 1929 (13.8) 1858 (12.5) 8628 (11.4)
Sodium level, median (IQR),
mEq/L
137.0 (134.0-139.0) 137.0 (134.0-140.0) 137.0 (134.0-139.0) 137.0 (134.0-139.0) 137.0 (134.0-139.0)
MELD score, median (IQR)a 15.0 (11.0-22.0) 16.0 (11.0-25.0) 16.0 (12.0-22.0) 17.0 (12.0-25.0) 16.0 (11.0-24.0)
HCC 5871 (25.5) 7018 (29.4) 3041 (21.7) 3812 (25.6) 19 742 (26.1)
Dialysis 1692 (7.4) 2138 (9.0) 880 (6.3) 1259 (8.5) 5969 (7.9)
Diabetes 6102 (26.5) 6810 (28.5) 3818 (27.3) 4657 (31.3) 21 387 (28.2)
Educational attainment
None 98/21 554 (0.5) 98/22 833 (0.4) 30/12 497 (0.2) 28/14 139 (0.2) 254/71 023 (0.4)
Grade school 1372/21 554 (6.4) 1532/22 833 (6.7) 555/12 497 (4.4) 645/14 139 (4.6) 4104/71 023 (5.8)
High school 9216/21 554 (42.8) 9462/22 833 (41.4) 5183/12 497 (41.5) 5829/14 139 (41.2) 29 690/71 023 (41.8)
Some college 5553/21 554 (25.8) 5765/22 833 (25.2) 3536/12 497 (28.3) 3829/14 139 (27.1) 18 683/71 023 (26.3)
Associate or bachelor’s degree 3568/21 554 (16.6) 4113/22 833 (18.0) 2400/12 497 (19.2) 2792/14 139 (19.7) 12 873/71 023 (18.1)
Graduate degree 1747/21 554 (8.1) 1863/22 833 (8.2) 793/12 497 (6.3) 1016/14 139 (7.2) 5419/71 023 (7.6)
Working for income 4867 (21.1) 5266 (22.1) 2996 (21.4) 3236 (21.8) 16 365 (21.6)
Abbreviations: HBV, hepatitis B virus; HCC, hepatocellular carcinoma; HCV, hepatitis C
virus; IQR, interquartile range; MELD, Model for End-Stage Liver Disease; NASH,
nonalcoholic steatohepatitis.
SI conversion factor: To convert sodium level to millimoles per liter, multiply by 1.0.
a The MELD score is used to assess liver disease severity, and high MELD scores indicate
worse liver function.
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Differences in Wait-listing Rates of Racial/Ethnic Minorities Between
Expansion States vs Nonexpansion States
When controlling for state population, more patients have been wait-listed for LT in expansion states
compared with nonexpansion states since 2012 (Figure 2A), contributing to higher rates of wait-listing
of Black patients and Hispanic patients in expansion states (Figure 2C and D). Black patients and Hispanic
patients were statistically significantly more likely to be wait-listed in expansion states than in
nonexpansion states (IRR, 1.54 [95% CI, 1.44-1.64] for Black patients and 1.21 [95% CI, 1.15-1.28] for
Hispanic patients) (Figure 2C and D and eTable 1 in the Supplement), which remained true when patients
with HCV were excluded from the analysis (Figure 3C and D and eTable 2 in the Supplement).




































































































































































































2010 2011 2012 2013 2014 2015 2016 2017
Expansion states
Nonexpansion states
A-F, Patients of American Indian, Alaskan native, or Hawaiian/Pacific Islander descent and multiracial patients were categorized as other race/ethnicity. The vertical lines on either side
of the data markers represent the 95% CIs. The dotted light blue line indicates the year when Medicaid expansion occurred.
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Differences Between Wait-listing Rates of Racial/Ethnic Minorities
Before vs After Medicaid Expansion
Overall, wait-listing rates increased with time in expansion states and nonexpansion states in the post–
Medicaid expansion era (APC, 1.4% [95% CI, 0.3%-2.6%] for expansion states and 8.2% [95% CI, 6.6%-
9.7%] for nonexpansion states) (Figure 2A and eTable 3 in the Supplement). Specifically, in the post–
Medicaid expansion era, wait-listing rates increased with time in White patients and Hispanic patients in
both expansion states and nonexpansion states (Figure 2B and D and eTable 3 in the Supplement).
Among Black patients in the post–Medicaid expansion era, the wait-listing rate decreased with time in









































































































































































































2010 2011 2012 2013 2014 2015 2016 2017
Expansion states
Nonexpansion states
A-F, Patients of American Indian, Alaskan native, or Hawaiian/Pacific Islander descent and multiracial patients were categorized as other race/ethnicity. The vertical lines on either side
of the data markers represent the 95% CIs. The dotted light blue line indicates the year when Medicaid expansion occurred.
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expansion states (APC, −4.4%; 95% CI, −8.2% to −0.6%) but not in nonexpansion states (APC, 0.5%;
95% CI, −4.0% to 5.2%) (Figure 2C and eTable 3 in the Supplement).
The market release of DAAs for HCV occurred in 2014, the same year as Medicaid expansion.
When Black patients with HCV were excluded from the analysis, the wait-listing rates for Black
patients in expansion states no longer decreased and was stable (APC, 3.1%; 95% CI, −2.4% to 8.9%)
(Figure 3C and eTable 4 in the Supplement). The post–Medicaid expansion trends were similar in
White patients and Hispanic patients when patients with HCV were excluded (Figure 3B and D and
eTable 4 in the Supplement).
Contributions of Medicaid Expansion to Differences in Wait-listing Rates for
Racial/Ethnic Minorities
Given that wait-listing rates increased over time in the post–Medicaid expansion era among White
patients and Hispanic patients in expansion states, we sought to explore if this increase could be
attributed to Medicaid expansion. The actual rate of wait-listing of White Medicaid patients in
expansion states was not more than would have been predicted by pre–Medicaid expansion trends
(APC, 1.4%; 95% CI, −3.7% to 6.8%) (Figure 4B and eTable 5 and eTable 7 in the Supplement). In
White patients, the increased wait-listing could be attributed to higher rates of wait-listing patients
with private insurance than would have been predicted without Medicaid expansion (APC, 3.3%;
95% CI, 0.6%-5.2%) (eFigure 2, eTable 5, and eTable 7 in the Supplement). Hispanic Medicaid
patients were wait-listed at higher rates in the post–Medicaid expansion era than would have been





















































































































































A-D, The implications of Medicaid expansion for wait-listing trends in racial/ethnic minorities is shown. The shaded areas represent the 95% CIs. The dotted light blue line indicates
the year when Medicaid expansion occurred.
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predicted without Medicaid expansion, but this finding was true in expansion states and
nonexpansion states (APC, 10.6% [95% CI, 3.4%-18.2%] in expansion states; 21.2% [95% CI, 5.5%-
39.1%] in nonexpansion states) (Figure 4D and eTable 5 and eTable 7 in the Supplement). Black
Medicaid patients in expansion states were wait-listed at the same rate in the post–Medicaid
expansion era as would be predicted by pre–Medicaid expansion trends (APC, 4.5%; 95% CI, −6.8%
to 17.2%) (Figure 4C and eTable 5 and eTable 7 in the Supplement).
When patients with HCV were excluded from the analysis, Hispanic Medicaid patients were
statistically significantly more likely to be wait-listed in the post–Medicaid expansion era than would
have been predicted without Medicaid expansion (APC, 13.2%; 95% CI, 4.0%-23.2%) (eFigure 3,
eTable 6, and eTable 8 in the Supplement). In contrast, White Medicaid patients without HCV were
wait-listed at lower rates than would have been predicted in nonexpansion states (eFigure 3,
eTable 6, and eTable 8 in the Supplement).
This cohort included patients with HCC. To ensure that inclusion of this population of patients
did not change the results, each analysis was performed after excluding this group. There was no
statistically significant change in the magnitude or direction of the findings.
Discussion
Although the full burden of decompensated liver disease necessitating LT is unknown, data suggest that
there are fewer racial/ethnic minorities wait-listed for LT than one would predict based on their burden of
liver disease.1,2 One of the approaches to reducing racial/ethnic disparities in health care has been to ex-
pand insurance coverage.19 However, the path to LT is complex. It has been unclear how expanding in-
surance coverage might impact LT wait-listing trends for racial/ethnic minorities. Our data indicate that
where you live may be as important as insurance coverage because statistically significantly more Black
patients and Hispanic patients were wait-listed in expansion states compared with nonexpansion states
even before Medicaid expansion. We further demonstrate that the wait-listing rates for Black patients
with HCV is downtrending in expansion states but not nonexpansion states. Finally, Medicaid expansion
was associated with a higher rate of wait-listing of Hispanic patients without HCV. Although these data
are observational, they suggest an important association between Medicaid expansion and LT wait-
listing rates in Black patients and Hispanic patients with ESLD.
Black patients and Hispanic patients were between 21% and 54% more likely to be wait-listed
in expansion states compared with nonexpansion states. One might hypothesize that the burden of
HCV varies by race/ethnicity and by state, contributing to higher rates of wait-listing of racial/ethnic
minorities in expansion states. However, when patients with HCV were excluded from the analysis,
these differences remained. Geographic differences in access to LT have long been described and
were the premise behind the Institute of Medicine’s mandate to the LT community to develop an
allocation system that ensured equality in access to LT.20 Differences in LT center wait-listing
behavior are complex and subject to multiple factors, including competition in the area, regulatory
pressures, practice patterns, and local organ availability.1 Although these differences might explain
state and regional variations in wait-listing, it is not clear that they explain geographic differences in
wait-listing for racial/ethnic minorities.
We found that LT wait-listing rates increased in the post–Medicaid expansion era for White
patients and Hispanic patients in expansion states and nonexpansion states. The increase seen
among White patients was associated with higher wait-listing rates of White patients with private
insurance than would have been predicted without Medicaid expansion. In the full cohort of Hispanic
patients, there were increased wait-listing rates seen in both expansion states and nonexpansion
states, making it difficult to attribute the increased wait-listing rates to Medicaid expansion alone.
However, when patients with HCV were excluded from the analysis, statistically significantly more
Hispanic patients with non–HCV-related ESLD were wait-listed in expansion states than would have
been predicted if Medicaid expansion had not occurred. This observation was not seen in
nonexpansion states, suggesting an association between Medicaid expansion and wait-listing rates
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of Hispanic patients with non–HCV-related ESLD. Previous work in this area has yielded mixed
results. Two studies15,16 examining solid organ transplants found increases in the proportion of
Medicaid patients wait-listed for LT in expansion states after Medicaid expansion; however, there
was no information provided about the race/ethnicity of the population. A final study14 that included
the race/ethnicity of LT candidates found no difference in the number of patients wait-listed by
race/ethnicity after Medicaid expansion. However, that study was limited to 1 year of data. Those
previous studies also did not account for wait-listing trends that were already under way before
Medicaid expansion or explore trends in other insurance types. Because these policies particularly
impact racial/ethnic minorities, such nuances are relevant and important.
Wait-listing rates decreased for Black patients in expansion states; however, when patients with
HCV were excluded, there was a non–statistically significant change in wait-listing rates. This finding
would suggest that the decreased wait-listing rate seen in Black patients in expansion states
contributed to lower rates of wait-listing in patients with HCV. This trend was not seen in
nonexpansion states, suggesting that the downward trend seen in Black patients was not secondary
to the market release of DAAs and HCV treatment alone. Such trends may be associated with
increased access to DAA therapy in expansion states secondary to Medicaid expansion. Medicaid
requirements for DAA therapy eligibility vary by state; however, there have been state-based
initiatives to increase access to therapy for as many Medicaid patients with chronic HCV as possible.21
Strengths and Limitations
A strength of our study is its large sample size that includes a diverse population of patients with
ESLD. This population is also the most contemporary such cohort examined, including multiple years
of post–Medicaid expansion data. Given the complex landscape of LT allocation, we also used
methods to attempt to account for trends that may have already been in process before Medicaid
expansion. We explored non-Medicaid insurance types to identify their contribution to overall
trends. Finally, we controlled for changes in state populations so that differences in trends between
expansion states and nonexpansion states could be better compared.
Our study also has limitations. There are no clear data on the number of patients with each
cause of ESLD in every state, so we could not control for both state population and each cause of
disease individually. However, exclusion of patients with HCV allowed exploration of important
questions about the impact of the market release of DAAs. The ACA included policies beyond just
Medicaid expansion, and it is possible that these changes also impacted the results of the present
study. Finally, we were unable to explore the reasons why Black patients and Hispanic patients were
statistically significantly more likely to be wait-listed in expansion states vs nonexpansion states.
Conclusions
There are 2 important observations of our study. First, where a patient lives could impact the likelihood
of LT wait-listing for racial/ethnic minority patients. Second, Medicaid expansion may be associated with
LT wait-listing trends for Black patients and Hispanic patients. In the current political climate in which
changes to health care policy and coverage are being regularly debated, it is important to understand the
potential impact that expanded coverage has had for vulnerable populations. Future studies should
explore geographic and other barriers to LT referral and wait-listing.
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